Novo Nordisk A/S (NVO) PS Ratio: 3.78
Is Novo Nordisk A/S’s P/S ratio high or low?
Novo Nordisk A/S's P/S ratio of 3.78 is 65% below its 5-year average of 10.85, near the low end of its 5-year range (3.30–18.54).
As of Wednesday, June 17, 2026. 22.23% below its 12-month average of 4.86.
NVO PS Ratio Chart
NVO Average PS Ratio Chart
NVO Current vs Average PS Ratio Chart
NVO PS Ratio Metrics
PS RATIO
3.78
PS RATIO AVG TTM
4.86
PS RATIO AVG 3Y
10.45
PS RATIO AVG 5Y
10.85
PS RATIO AVG 10Y
8.99
PS RATIO AVG 15Y
7.85
PS RATIO AVG 20Y
6.94
CURRENT VS TTM AVG
-22.23%
CURRENT VS 3Y AVG
-63.81%
CURRENT VS 5Y AVG
-65.17%
CURRENT VS 10Y AVG
-57.93%
CURRENT VS 15Y AVG
-51.84%
CURRENT VS 20Y AVG
-45.57%
NVO Competitors' PS Ratio
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 3.78 | 4.86 | 10.45 | 10.85 |
| Amgen Inc. (AMGN)vs › | $187.59B | 5.08 | 4.89 | 5.13 | 5.11 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 3.90 | 4.39 | 4.66 | 4.97 |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 5.37 | 5.42 | 4.32 | 3.91 |
| Abbott Laboratories (ABT)vs › | $157.84B | 3.51 | 4.71 | 4.80 | 4.78 |
| Pfizer Inc. (PFE)vs › | $148.41B | 2.36 | 2.32 | 2.45 | 2.85 |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 14.18 | 18.61 | 19.86 | 18.98 |
| Danaher Corporation (DHR)vs › | $128.06B | 5.21 | 6.00 | 6.59 | 6.42 |
| CVS Health Corporation (CVS)vs › | $127.73B | 0.32 | 0.25 | 0.24 | 0.31 |
| Stryker Corporation (SYK)vs › | $115.45B | 4.61 | 5.71 | 6.02 | 5.84 |
P/S vs. its own history
At 3.78, P/S is cheaper than usual, sitting higher than 6% of its 20-year history.
20-year low
2.76
median
6.81
20-year high
18.54
Sales Valuation
P/S Ratio
3.78
Market Cap / Annual Revenue
Novo Nordisk A/S PS Ratio Formula & Definition
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S PS Ratio FAQ
- What is the P/S ratio for Novo Nordisk A/S (NVO)?
- The P/S ratio for NVO stock is 3.78.
- Is Novo Nordisk A/S's P/S ratio high or low?
- Novo Nordisk A/S's P/S ratio of 3.78 is 65% below its 5-year average of 10.85, near the low end of its 5-year range (3.30–18.54).
- What is the TTM average P/S ratio for Novo Nordisk A/S (NVO)?
- The TTM average P/S ratio for NVO stock is 4.86.
- What is the 3Y average P/S ratio for Novo Nordisk A/S (NVO)?
- The 3Y average P/S ratio for NVO stock is 10.45.
- What is the 5Y average P/S ratio for Novo Nordisk A/S (NVO)?
- The 5Y average P/S ratio for NVO stock is 10.85.
- What is the 10Y average P/S ratio for Novo Nordisk A/S (NVO)?
- The 10Y average P/S ratio for NVO stock is 8.99.
- What is the 15Y average P/S ratio for Novo Nordisk A/S (NVO)?
- The 15Y average P/S ratio for NVO stock is 7.85.
- What is the 20Y average P/S ratio for Novo Nordisk A/S (NVO)?
- The 20Y average P/S ratio for NVO stock is 6.94.
Novo Nordisk A/S PS Ratio History
| DATE | PS RATIO |
|---|---|
| 2026-06-17 | 3.78 |
| 2026-06-16 | 3.78 |
| 2026-06-15 | 3.82 |
| 2026-06-12 | 3.81 |
| 2026-06-11 | 3.82 |
| 2026-06-10 | 3.72 |
| 2026-06-09 | 3.67 |
| 2026-06-08 | 3.56 |
| 2026-06-05 | 3.73 |
| 2026-06-04 | 3.80 |
| 2026-06-03 | 3.65 |
| 2026-06-02 | 3.73 |
| 2026-06-01 | 3.83 |
| 2026-05-29 | 3.96 |
| 2026-05-28 | 3.95 |
| 2026-05-27 | 3.87 |
| 2026-05-26 | 3.84 |
| 2026-05-22 | 3.91 |
| 2026-05-21 | 3.86 |
| 2026-05-20 | 3.92 |
| 2026-05-19 | 3.85 |
| 2026-05-18 | 3.85 |
| 2026-05-15 | 3.89 |
| 2026-05-14 | 3.98 |
| 2026-05-13 | 4.09 |
| 2026-05-12 | 4.08 |
| 2026-05-11 | 4.03 |
| 2026-05-08 | 4.00 |
| 2026-05-07 | 3.98 |
| 2026-05-06 | 3.98 |
| 2026-05-05 | 4.19 |
| 2026-05-04 | 4.15 |
| 2026-05-01 | 4.10 |
| 2026-04-30 | 3.95 |
| 2026-04-29 | 3.77 |
| 2026-04-28 | 3.85 |
| 2026-04-27 | 3.85 |
| 2026-04-24 | 3.85 |
| 2026-04-23 | 3.60 |
| 2026-04-22 | 3.66 |
| 2026-04-21 | 3.68 |
| 2026-04-20 | 3.78 |
| 2026-04-17 | 3.79 |
| 2026-04-16 | 3.82 |
| 2026-04-15 | 3.81 |
| 2026-04-14 | 3.67 |
| 2026-04-13 | 3.55 |
| 2026-04-10 | 3.51 |
| 2026-04-09 | 3.50 |
| 2026-04-08 | 3.51 |
| 2026-04-07 | 3.45 |
| 2026-04-06 | 3.43 |
| 2026-04-02 | 3.46 |
| 2026-04-01 | 3.41 |
| 2026-03-31 | 3.43 |
| 2026-03-30 | 3.30 |
| 2026-03-27 | 3.37 |
| 2026-03-26 | 3.40 |
| 2026-03-25 | 3.40 |
| 2026-03-24 | 3.45 |
| 2026-03-23 | 3.44 |
| 2026-03-20 | 3.41 |
| 2026-03-19 | 3.47 |
| 2026-03-18 | 3.50 |
| 2026-03-17 | 3.59 |
| 2026-03-16 | 3.61 |
| 2026-03-13 | 3.55 |
| 2026-03-12 | 3.55 |
| 2026-03-11 | 3.63 |
| 2026-03-10 | 3.62 |
| 2026-03-09 | 3.72 |
| 2026-03-06 | 3.61 |
| 2026-03-05 | 3.65 |
| 2026-03-04 | 3.60 |
| 2026-03-03 | 3.43 |
| 2026-03-02 | 3.53 |
| 2026-02-27 | 3.50 |
| 2026-02-26 | 3.52 |
| 2026-02-25 | 3.57 |
| 2026-02-24 | 3.61 |
| 2026-02-23 | 3.70 |
| 2026-02-20 | 4.43 |
| 2026-02-19 | 4.53 |
| 2026-02-18 | 4.60 |
| 2026-02-17 | 4.61 |
| 2026-02-13 | 4.63 |
| 2026-02-12 | 4.57 |
| 2026-02-11 | 4.55 |
| 2026-02-10 | 4.59 |
| 2026-02-09 | 4.61 |
| 2026-02-06 | 4.45 |
| 2026-02-05 | 4.05 |
| 2026-02-04 | 4.41 |
| 2026-02-03 | 4.70 |
| 2026-02-02 | 5.57 |
| 2026-01-30 | 5.62 |
| 2026-01-29 | 5.61 |
| 2026-01-28 | 5.70 |
| 2026-01-27 | 5.95 |
| 2026-01-26 | 6.05 |
| 2026-01-23 | 5.89 |
| 2026-01-22 | 5.88 |
| 2026-01-21 | 5.61 |
| 2026-01-20 | 5.74 |
| 2026-01-16 | 5.89 |
| 2026-01-15 | 5.40 |
| 2026-01-14 | 5.57 |
| 2026-01-13 | 5.64 |
| 2026-01-12 | 5.66 |
| 2026-01-09 | 5.56 |
| 2026-01-08 | 5.42 |
| 2026-01-07 | 5.35 |
| 2026-01-06 | 5.32 |
| 2026-01-05 | 5.21 |
| 2026-01-02 | 4.95 |
| 2025-12-31 | 4.81 |
| 2025-12-30 | 4.84 |
| 2025-12-29 | 4.87 |
| 2025-12-26 | 4.95 |
| 2025-12-24 | 4.97 |
| 2025-12-23 | 4.88 |
| 2025-12-22 | 4.55 |
| 2025-12-19 | 4.55 |
| 2025-12-18 | 4.50 |
| 2025-12-17 | 4.52 |
| 2025-12-16 | 4.63 |
| 2025-12-15 | 4.76 |
| 2025-12-12 | 4.74 |
| 2025-12-11 | 4.75 |
| 2025-12-10 | 4.64 |
| 2025-12-09 | 4.38 |
| 2025-12-08 | 4.42 |
| 2025-12-05 | 4.52 |
| 2025-12-04 | 4.54 |
| 2025-12-03 | 4.50 |
| 2025-12-02 | 4.48 |
| 2025-12-01 | 4.58 |
| 2025-11-28 | 4.67 |
| 2025-11-26 | 4.60 |
| 2025-11-25 | 4.45 |
| 2025-11-24 | 4.25 |
| 2025-11-21 | 4.50 |
| 2025-11-20 | 4.50 |
| 2025-11-19 | 4.63 |
| 2025-11-18 | 4.50 |
| 2025-11-17 | 4.58 |
| 2025-11-14 | 4.56 |
| 2025-11-13 | 4.65 |
| 2025-11-12 | 4.75 |
| 2025-11-11 | 4.65 |
| 2025-11-10 | 4.34 |
| 2025-11-07 | 4.32 |
| 2025-11-06 | 4.40 |
| 2025-11-05 | 4.58 |
| 2025-11-04 | 4.67 |
| 2025-11-03 | 4.76 |
| 2025-10-31 | 4.79 |
| 2025-10-30 | 4.85 |
| 2025-10-29 | 4.97 |
| 2025-10-28 | 5.04 |
| 2025-10-27 | 5.12 |
| 2025-10-24 | 5.13 |
| 2025-10-23 | 5.15 |
| 2025-10-22 | 5.17 |
| 2025-10-21 | 5.30 |
| 2025-10-20 | 5.40 |
| 2025-10-17 | 5.26 |
| 2025-10-16 | 5.43 |
| 2025-10-15 | 5.49 |
| 2025-10-14 | 5.49 |
| 2025-10-13 | 5.57 |
| 2025-10-10 | 5.51 |
| 2025-10-09 | 5.68 |
| 2025-10-08 | 5.77 |
| 2025-10-07 | 5.72 |
| 2025-10-06 | 5.78 |
| 2025-10-03 | 5.77 |
| 2025-10-02 | 5.69 |
| 2025-10-01 | 5.73 |
| 2025-09-30 | 5.37 |
| 2025-09-29 | 5.37 |
| 2025-09-26 | 5.38 |
| 2025-09-25 | 5.43 |
| 2025-09-24 | 5.69 |
| 2025-09-23 | 5.77 |
| 2025-09-22 | 5.88 |
| 2025-09-19 | 5.95 |
| 2025-09-18 | 5.99 |
| 2025-09-17 | 5.64 |
| 2025-09-16 | 5.54 |
| 2025-09-15 | 5.39 |
| 2025-09-12 | 5.31 |
| 2025-09-11 | 5.26 |
| 2025-09-10 | 5.26 |
| 2025-09-09 | 5.26 |
| 2025-09-08 | 5.26 |
| 2025-09-05 | 5.35 |
| 2025-09-04 | 5.44 |
| 2025-09-03 | 5.49 |
| 2025-09-02 | 5.46 |
| 2025-08-29 | 5.47 |
| 2025-08-28 | 5.43 |
| 2025-08-27 | 5.47 |
| 2025-08-26 | 5.36 |
| 2025-08-25 | 5.46 |
| 2025-08-22 | 5.52 |
| 2025-08-21 | 5.37 |
| 2025-08-20 | 5.26 |
| 2025-08-19 | 5.30 |
| 2025-08-18 | 5.20 |
| 2025-08-15 | 5.08 |
| 2025-08-14 | 4.93 |
| 2025-08-13 | 4.93 |
| 2025-08-12 | 4.82 |
| 2025-08-11 | 4.83 |
| 2025-08-08 | 4.95 |
| 2025-08-07 | 4.72 |
| 2025-08-06 | 4.39 |
| 2025-08-05 | 4.81 |
| 2025-08-04 | 4.98 |
| 2025-08-01 | 4.91 |
| 2025-07-31 | 4.80 |
| 2025-07-30 | 5.10 |
| 2025-07-29 | 5.50 |
| 2025-07-28 | 7.03 |
| 2025-07-25 | 7.31 |
| 2025-07-24 | 7.21 |
| 2025-07-23 | 7.14 |
| 2025-07-22 | 6.81 |
| 2025-07-21 | 6.62 |
| 2025-07-18 | 6.56 |
| 2025-07-17 | 6.66 |
| 2025-07-16 | 6.83 |
| 2025-07-15 | 6.85 |
| 2025-07-14 | 7.03 |
| 2025-07-11 | 7.03 |
| 2025-07-10 | 7.24 |
| 2025-07-09 | 7.10 |
| 2025-07-08 | 7.10 |
| 2025-07-07 | 7.07 |
| 2025-07-03 | 7.05 |
| 2025-07-02 | 7.12 |
| 2025-07-01 | 7.12 |
| 2025-06-30 | 7.04 |
| 2025-06-27 | 6.98 |
| 2025-06-26 | 6.90 |
| 2025-06-25 | 6.87 |
| 2025-06-24 | 7.21 |
| 2025-06-23 | 7.11 |
| 2025-06-20 | 7.52 |
| 2025-06-18 | 7.55 |
| 2025-06-17 | 7.58 |
| 2025-06-16 | 7.85 |
| 2025-06-13 | 8.14 |
| 2025-06-12 | 8.26 |
| 2025-06-11 | 8.03 |
| 2025-06-10 | 8.09 |
| 2025-06-09 | 7.69 |
| 2025-06-06 | 7.61 |
| 2025-06-05 | 7.41 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar